Annexon, Inc. (NASDAQ:ANNX) Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP increased its position in Annexon, Inc. (NASDAQ:ANNX) by 10.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,581 shares of the company’s stock after purchasing an additional 3,355 shares during the quarter. GSA Capital Partners LLP’s holdings in Annexon were worth $205,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in Annexon by 10,482.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,323,704 shares of the company’s stock valued at $9,492,000 after acquiring an additional 1,311,195 shares during the last quarter. Vanguard Group Inc. increased its stake in Annexon by 96.4% during the first quarter. Vanguard Group Inc. now owns 3,747,655 shares of the company’s stock valued at $26,871,000 after purchasing an additional 1,839,329 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Annexon by 16.1% in the second quarter. Point72 Asset Management L.P. now owns 5,989,017 shares of the company’s stock worth $29,346,000 after acquiring an additional 832,617 shares during the last quarter. Point72 Europe London LLP bought a new stake in Annexon in the 2nd quarter valued at about $1,150,000. Finally, Mutual of America Capital Management LLC bought a new position in Annexon in the 2nd quarter worth approximately $3,134,000.

Analysts Set New Price Targets

ANNX has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and set a $16.00 price target on shares of Annexon in a research report on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Annexon in a report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Annexon has an average rating of “Buy” and a consensus price target of $15.80.

Insider Transactions at Annexon

In related news, EVP Ted Yednock sold 5,500 shares of the company’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $5.64, for a total value of $31,020.00. Following the completion of the sale, the executive vice president now directly owns 10,000 shares in the company, valued at approximately $56,400. This represents a 35.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold 20,908 shares of company stock valued at $135,768 in the last three months. Corporate insiders own 12.67% of the company’s stock.

Annexon Trading Down 0.6 %

NASDAQ ANNX opened at $5.14 on Monday. The company has a market capitalization of $547.87 million, a PE ratio of -4.90 and a beta of 1.23. Annexon, Inc. has a 1-year low of $2.27 and a 1-year high of $8.40. The firm’s fifty day simple moving average is $6.79 and its 200-day simple moving average is $5.94.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.